{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "a607cb2c-1ac1-4904-9953-a8a34697daec",
   "metadata": {
    "tags": []
   },
   "source": [
    "## Imports"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "61c15413-b5ac-42c3-8da5-e7ff8832efb7",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/catarinasilva/anaconda3/lib/python3.11/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:11: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
      "  from tqdm.autonotebook import tqdm, trange\n"
     ]
    }
   ],
   "source": [
    "# === Standard Library Imports ===\n",
    "import os\n",
    "import re\n",
    "import csv\n",
    "import json\n",
    "import time\n",
    "import glob\n",
    "import pickle\n",
    "import random\n",
    "from datetime import datetime\n",
    "from collections import defaultdict, deque\n",
    "\n",
    "# === Web & API Requests ===\n",
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "\n",
    "# === PDF Handling ===\n",
    "from PyPDF2 import PdfReader\n",
    "import pdfplumber\n",
    "\n",
    "# === Machine Learning & Embeddings ===\n",
    "import numpy as np\n",
    "import torch\n",
    "import faiss\n",
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "# === OpenAI & Azure OpenAI ===\n",
    "import tiktoken\n",
    "import openai\n",
    "from openai import OpenAIError, RateLimitError, AzureOpenAI\n",
    "from langchain_openai import AzureOpenAIEmbeddings, AzureOpenAI  # (duplicate module name kept)\n",
    "\n",
    "# === Google Gemini ===\n",
    "import google.generativeai as genai\n",
    "\n",
    "# === ChromaDB ===\n",
    "import chromadb\n",
    "from langchain_chroma import Chroma\n",
    "\n",
    "# === LangChain ===\n",
    "from langchain_openai import AzureOpenAIEmbeddings  # (duplicate kept as required)\n",
    "\n",
    "# === Selenium (Web Scraping) ===\n",
    "from selenium import webdriver\n",
    "from selenium.webdriver.common.by import By\n",
    "from selenium.webdriver.chrome.service import Service\n",
    "from selenium.webdriver.chrome.options import Options\n",
    "from selenium.webdriver.support.ui import WebDriverWait\n",
    "from selenium.webdriver.support import expected_conditions as EC\n",
    "from selenium.common.exceptions import TimeoutException, NoSuchElementException\n",
    "\n",
    "# === Utilities & Progress Bars ===\n",
    "from tqdm import tqdm\n",
    "\n",
    "# === Repeated Imports (kept, as requested not to remove) ===\n",
    "import os\n",
    "import json\n",
    "import torch\n",
    "import time\n",
    "import tiktoken\n",
    "import google.generativeai as genai\n",
    "from tqdm import tqdm\n",
    "from langchain_chroma import Chroma\n",
    "from sentence_transformers import SentenceTransformer\n",
    "\n",
    "# === Faulty Custom Imports (kept but syntactically corrected) ===\n",
    "from src.utils.file_utils import zip_directory\n",
    "from src.preprocessing.nlp.web_scraping_utils import *  \n",
    "from src.preprocessing.nlp.pdf_preprocessing import *      \n",
    "\n",
    "# === Environment Variables ===\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "\n",
    "# === Custom Imports (Block 2) ===\n",
    "from src.utils.file_utils import zip_directory\n",
    "from src.preprocessing.nlp.web_scraping_utils import *\n",
    "from src.preprocessing.nlp.pdf_preprocessing import (\n",
    "    extract_text_from_pdf,\n",
    "    save_to_json,\n",
    "    process_multiple_pdfs\n",
    ")\n",
    "\n",
    "from src.nlp.utils.tex_cleaning import (\n",
    "    clean_text,\n",
    "    is_navigation_item,\n",
    "    clean_website_data,\n",
    "    clean_pdf_data,\n",
    "    clean_list_based_json,\n",
    "    process_json_files\n",
    ")\n",
    "\n",
    "from src.nlp.api.config import openai_client, embedding_function, genai\n",
    "\n",
    "from src.nlp.rag.chromadb import (\n",
    "    store_embeddings_in_chroma,\n",
    "    process_and_store_embeddings,\n",
    "    store_embeddings_in_chroma_openai,\n",
    "    process_and_store_embeddings_openai\n",
    ")\n",
    "\n",
    "from src.nlp.rag.embeddings_utils import structure_documents, load_all_embeddings\n",
    "from src.nlp.rag.embeddings import GeminiEmbeddings, MiniLMEmbeddings, get_embedding\n",
    "from src.nlp.rag.embeddings_openai import structure_documents_openai, get_embedding_openai\n",
    "\n",
    "from src.nlp.rag.retrieval import (\n",
    "    retrieve_top_k_chromadb,\n",
    "    hybrid_retrieval,\n",
    "    combined_retrieval\n",
    ")\n",
    "\n",
    "from src.nlp.prompt.prompt import generate_structured_prompt_tnm\n",
    "\n",
    "from src.nlp.api.gpt4omini import (\n",
    "    get_azure_openai_rate_limits,\n",
    "    enforce_rate_limits_openai,\n",
    "    generate_response_gpt4o\n",
    ")\n",
    "\n",
    "from src.nlp.api.gemini_2flash import generate_response_gemini\n",
    "\n",
    "from src.nlp.rag.chunking import chunk_text, chunk_text_openai\n",
    "\n",
    "from src.nlp.rag.rag_pipeline import retrieval_and_response_pipeline"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "372929c0-d3c6-4892-8319-5ce26b784db3",
   "metadata": {
    "tags": []
   },
   "source": [
    "### Dinamic Websites"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "66780672-500c-470d-b39a-2709e7518f29",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "# List of URLs to scrape - Website American Cancer Association\n",
    "urls = [\n",
    "    # American Cancer Association\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/causes-risks-prevention/risk-factors.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/causes-risks-prevention/what-causes.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/causes-risks-prevention/prevention.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/detection.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/lung-nodules.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/signs-symptoms.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/how-diagnosed.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/staging-nsclc.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/staging-sclc.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html\",\n",
    "    \n",
    "    ## Non Small Cell LC\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/surgery.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/radiofrequency-ablation.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/radiation-therapy.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/tumor-treating-fields.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/chemotherapy.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/immunotherapy.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/palliative.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/by-stage.html\",\n",
    "    \n",
    "    ## Small Cell LC\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/chemotherapy.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/immunotherapy.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/radiation-therapy.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/surgery.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/palliative.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/treating-small-cell/by-stage.html\",\n",
    "    \n",
    "    ## SCLC NSCLC\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/if-you-have-non-small-cell-lung-cancer-nsclc.html\",\n",
    "    \"https://www.cancer.org/cancer/types/lung-cancer/if-you-have-small-cell-lung-cancer-sclc.html\",\n",
    "    \n",
    "    # NCI\n",
    "    ## Patient version\n",
    "    \"https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq\",\n",
    "    \"https://www.cancer.gov/types/lung/patient/small-cell-lung-treatment-pdq\",\n",
    "    \n",
    "    ## Health professional version\n",
    "    \"https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq\",\n",
    "    \"https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq\"\n",
    "]\n",
    "    \n",
    "output_directory = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/scraped_data/websites/\"\n",
    "output_csv_file = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/scraped_data/websites.csv\"\n",
    "scrape_and_store_pages(urls, output_directory, output_csv_file)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2ceb4185-6bf1-48e3-a838-65f3ad6a6af9",
   "metadata": {
    "tags": []
   },
   "source": [
    "### PDF"
   ]
  },
  {
   "cell_type": "raw",
   "id": "cdbcd3f1-f122-427f-8279-bc2ed5875f87",
   "metadata": {
    "tags": []
   },
   "source": [
    "pdf_paths = [\n",
    "    \"/Users/catarinasilva/Desktop/Master Thesis/LLM lung cancer/Lung Cancer guidelines/NCCN (national comprehensive cancer network)/NSLC-patient-guideline.pdf\",\n",
    "    \"/Users/catarinasilva/Desktop/Master Thesis/LLM lung cancer/Lung Cancer guidelines/NCCN (national comprehensive cancer network)/SCLC-patient-guideline.pdf\",\n",
    "    \"/Users/catarinasilva/Desktop/Master Thesis/LLM lung cancer/Lung Cancer guidelines/ESMO/Small-cell lung cancer.pdf\"\n",
    "]\n",
    "output_dir = \"/Users/catarinasilva/Desktop/Master Thesis/LLM lung cancer/scraped_data_NCCN_ESMO.json\"\n",
    "\n",
    "# Process the PDFs\n",
    "process_multiple_pdfs(pdf_paths, output_dir)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f3ded831-e614-4535-b164-e17e42357eda",
   "metadata": {
    "tags": []
   },
   "source": [
    "## Data cleaning"
   ]
  },
  {
   "cell_type": "raw",
   "id": "444ac895-f9bf-45df-b2d1-c636aa7f4284",
   "metadata": {
    "tags": []
   },
   "source": [
    "# Example Usage\n",
    "input_directory = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/scraped_data/websites\"  # Replace with your actual input directory\n",
    "output_directory = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/scraped_data/cleaned\"  # Replace with your actual output directory\n",
    "\n",
    "process_json_files(input_directory, output_directory)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "577dfd82-93ac-4581-b025-56c226a5f3f4",
   "metadata": {
    "tags": []
   },
   "source": [
    "## Embedding data - models"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "44e332fa-f701-41c8-a2a6-0b8994e5789e",
   "metadata": {},
   "source": [
    "**Embedding Models**\n",
    "\n",
    "| **Model** | **Provider** | **Size** | **Best For** |\n",
    "|-----------|------------|---------|------------|\n",
    "| `all-MiniLM-L6-v2` | **Sentence-Transformers** | **22M** | General text retrieval |\n",
    "| `text-embedding-ada-002` | **OpenAI** | Proprietary | High-quality embeddings for various NLP tasks |\n",
    "| `gemini-text-embedding-004` | **Google** | Proprietary | Optimized for Google AI applications |"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "14b67c5a-4d6d-4eff-bbae-1be825355296",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "# === Configure Torch to Use MPS (Mac), CUDA (NVIDIA), or CPU ===\n",
    "device = \"mps\" if torch.backends.mps.is_available() else \"cpu\""
   ]
  },
  {
   "cell_type": "markdown",
   "id": "abdab5cd-6b27-454a-b038-fd3f6b3bd36e",
   "metadata": {
    "tags": []
   },
   "source": [
    "#### Get OpenAI limits"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "df340939-4552-4595-bfbd-3c956858b3e8",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Azure OpenAI API Rate Limits:\n",
      "Requests Per Minute (RPM): 2500\n",
      "Remaining Requests: 2499\n",
      "Tokens Per Minute (TPM): 250000\n",
      "Remaining Tokens: 249997\n"
     ]
    }
   ],
   "source": [
    "# Initialize Azure OpenAI Client\n",
    "openai_client = AzureOpenAI(\n",
    "    azure_endpoint=endpoint,\n",
    "    api_key=subscription_key,\n",
    "    api_version=api_version,\n",
    ")\n",
    "\n",
    "# Configure Azure OpenAI Embeddings\n",
    "embedding_function = AzureOpenAIEmbeddings(\n",
    "    azure_endpoint=endpoint,\n",
    "    api_key=subscription_key,\n",
    "    azure_deployment=\"TextEmbeddings\",  # Ensure this is the correct deployment name in Azure\n",
    "    openai_api_version=api_version,\n",
    "    max_retries=50\n",
    ")\n",
    "\n",
    "# Run the function\n",
    "get_azure_openai_rate_limits()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "9843e87a-c23f-4f84-b436-684876a74219",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "models/chat-bison-001\n",
      "models/text-bison-001\n",
      "models/embedding-gecko-001\n",
      "models/gemini-1.0-pro-vision-latest\n",
      "models/gemini-pro-vision\n",
      "models/gemini-1.5-pro-latest\n",
      "models/gemini-1.5-pro-001\n",
      "models/gemini-1.5-pro-002\n",
      "models/gemini-1.5-pro\n",
      "models/gemini-1.5-flash-latest\n",
      "models/gemini-1.5-flash-001\n",
      "models/gemini-1.5-flash-001-tuning\n",
      "models/gemini-1.5-flash\n",
      "models/gemini-1.5-flash-002\n",
      "models/gemini-1.5-flash-8b\n",
      "models/gemini-1.5-flash-8b-001\n",
      "models/gemini-1.5-flash-8b-latest\n",
      "models/gemini-1.5-flash-8b-exp-0827\n",
      "models/gemini-1.5-flash-8b-exp-0924\n",
      "models/gemini-2.0-flash-exp\n",
      "models/gemini-2.0-flash\n",
      "models/gemini-2.0-flash-001\n",
      "models/gemini-2.0-flash-exp-image-generation\n",
      "models/gemini-2.0-flash-lite-001\n",
      "models/gemini-2.0-flash-lite\n",
      "models/gemini-2.0-flash-lite-preview-02-05\n",
      "models/gemini-2.0-flash-lite-preview\n",
      "models/gemini-2.0-pro-exp\n",
      "models/gemini-2.0-pro-exp-02-05\n",
      "models/gemini-exp-1206\n",
      "models/gemini-2.0-flash-thinking-exp-01-21\n",
      "models/gemini-2.0-flash-thinking-exp\n",
      "models/gemini-2.0-flash-thinking-exp-1219\n",
      "models/learnlm-1.5-pro-experimental\n",
      "models/gemma-3-27b-it\n",
      "models/embedding-001\n",
      "models/text-embedding-004\n",
      "models/gemini-embedding-exp-03-07\n",
      "models/gemini-embedding-exp\n",
      "models/aqa\n",
      "models/imagen-3.0-generate-002\n"
     ]
    }
   ],
   "source": [
    "# List available models\n",
    "models = genai.list_models()\n",
    "\n",
    "# Print models\n",
    "for model in models:\n",
    "    print(model.name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "20670b99-e851-41a2-8283-4f1e4e2c938b",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "# === Tokenizer for Chunking ===\n",
    "enc = tiktoken.get_encoding(\"cl100k_base\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "53354394-7e27-4e00-9f49-f6fe8576ad65",
   "metadata": {
    "tags": []
   },
   "source": [
    "### Gemini embeddings + MiniLM embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "97aad8f0-c777-472d-a733-06b6c9c05ff2",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Using device: mps\n"
     ]
    }
   ],
   "source": [
    " os.environ[\"TOKENIZERS_PARALLELISM\"] = \"false\"\n",
    "\n",
    "# === Set Device to Use Mac MPS (Metal Performance Shaders) ===\n",
    "device = \"mps\" if torch.backends.mps.is_available() else \"cpu\"\n",
    "print(f\"Using device: {device}\")\n",
    "\n",
    "# === Define Experimental Parameters ===\n",
    "CHUNK_OVERLAPS = [0.2]  # Overlap variations\n",
    "\n",
    "# Define chunk sizes per model type\n",
    "CHUNK_SIZES = {\n",
    "    \"gemini\": [1000],  # Gemini models\n",
    "    \"local\": [500]     # Local models (MiniLM, MPNet)\n",
    "}\n",
    "\n",
    "# === Storage Paths ===\n",
    "DATA_FOLDER = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/scraped_data/cleaned\"\n",
    "STORAGE_DIR = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings\"\n",
    "CHROMA_PATHS = {\n",
    "    \"gemini\": os.path.join(STORAGE_DIR, \"chroma_db_gemini\"),\n",
    "    \"local\": os.path.join(STORAGE_DIR, \"chroma_db_minilm\"),\n",
    "}\n",
    "\n",
    "for path in CHROMA_PATHS.values():\n",
    "    os.makedirs(path, exist_ok=True)\n",
    "\n",
    "# === Define Embedding Models ===\n",
    "EMBEDDING_MODELS = {\n",
    "    \"all-MiniLM-L6-v2\": \"sentence-transformers/all-MiniLM-L6-v2\",\n",
    "    \"gemini\": \"gemini\"\n",
    "}\n",
    "\n",
    "\n",
    "# === Initialize ChromaDB with the Correct Embedding Classes ===\n",
    "db_gemini = Chroma(persist_directory=CHROMA_PATHS[\"gemini\"], embedding_function=GeminiEmbeddings(api_key=os.getenv(\"GEMINI_API_KEY\", \"AIzaSyAsBeecsEuVOeo7zanoC7yfC5w97hi4ffM\")))\n",
    "db_minilm = Chroma(persist_directory=CHROMA_PATHS[\"local\"], embedding_function=MiniLMEmbeddings(device=device))"
   ]
  },
  {
   "cell_type": "raw",
   "id": "b3b880d1-064e-4512-b2fb-acf897c46a29",
   "metadata": {
    "tags": []
   },
   "source": [
    "process_and_store_embeddings()"
   ]
  },
  {
   "cell_type": "raw",
   "id": "8d7f3216-4272-442c-9d32-49200aad934a",
   "metadata": {},
   "source": [
    "Found 38 JSON files.\n",
    "Structured 994 documents.\n",
    "Processing Documents: 100%|█████████████████| 994/994 [2:21:49<00:00,  8.56s/it]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "bf259ce1-40b0-4d2c-afda-fad539537528",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Total embeddings stored in ChromaDB - Gemini: 1327\n",
      " Total embeddings stored in ChromaDB - MiniLM: 1837\n"
     ]
    }
   ],
   "source": [
    "print(\" Total embeddings stored in ChromaDB - Gemini:\", db_gemini._collection.count())\n",
    "print(\" Total embeddings stored in ChromaDB - MiniLM:\", db_minilm._collection.count())"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d81504df-890a-44a7-8a1d-8b91ee71d7e7",
   "metadata": {
    "tags": []
   },
   "source": [
    "### Open AI embedings - text-embedding-ada-002"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "3963c33d-82d4-45ab-946d-353c95097936",
   "metadata": {
    "tags": []
   },
   "outputs": [],
   "source": [
    "# === Define Azure OpenAI Rate Limits ===\n",
    "MAX_REQUESTS_PER_MINUTE = 2500  \n",
    "MAX_TOKENS_PER_MINUTE = 250000  \n",
    "REQUEST_TIMESTAMPS = deque(maxlen=MAX_REQUESTS_PER_MINUTE)  \n",
    "TOKENS_USED = 0  \n",
    "\n",
    "# === Define Chunking Parameters ===\n",
    "CHUNK_OVERLAPS = [0.2]  \n",
    "CHUNK_SIZES = {\n",
    "    \"openai\": [1000]  \n",
    "}\n",
    "\n",
    "# === Storage Paths ===\n",
    "DATA_FOLDER = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/scraped_data/cleaned\"\n",
    "STORAGE_DIR = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings\"\n",
    "CHROMA_DB_DIR = os.path.join(STORAGE_DIR, \"chroma_db_openAI\")\n",
    "\n",
    "# Ensure directories exist\n",
    "os.makedirs(STORAGE_DIR, exist_ok=True)\n",
    "os.makedirs(CHROMA_DB_DIR, exist_ok=True)\n",
    "\n",
    "# Initialize ChromaDB\n",
    "db = Chroma(persist_directory=CHROMA_DB_DIR, embedding_function=embedding_function)"
   ]
  },
  {
   "cell_type": "raw",
   "id": "234a7292-9af3-4e4e-a963-667f62c67d71",
   "metadata": {
    "tags": []
   },
   "source": [
    "process_and_store_embeddings_openai()"
   ]
  },
  {
   "cell_type": "raw",
   "id": "a11d5d90-0a42-4f3a-8291-b0e06c8d7418",
   "metadata": {},
   "source": [
    "Found 38 JSON files.\n",
    "Structured 994 documents.\n",
    "Processing Documents: 100%|█████████████████| 994/994 [2:07:10<00:00,  7.68s/it]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "181aca92-802e-454b-85bb-5abc2299e89a",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Total embeddings stored in ChromaDB - OpenAI: 1327\n"
     ]
    }
   ],
   "source": [
    "print(\" Total embeddings stored in ChromaDB - OpenAI:\", db_openai._collection.count())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "bbda90ec-df69-407c-ad72-3621b5f2eff4",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Directory '/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings/chroma_db_openAI' successfully zipped to '/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings/chroma_db_openAI.zip'\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "'/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings/chroma_db_openAI.zip'"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Example usage\n",
    "directory_to_zip = \"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings/chroma_db_openAI\" \n",
    "zip_directory(directory_to_zip)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "08ab76c8-28dc-4681-86c8-2c19b0a8dea7",
   "metadata": {
    "tags": []
   },
   "source": [
    "## Retrieve"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "af5b4b81-7c9f-4d1f-97c7-eec7b2b52a82",
   "metadata": {
    "tags": []
   },
   "source": [
    "**Vector Storage Choice: ChromaDB**\n",
    "For this experiment, **ChromaDB** will be used as the vector storage system. ChromaDB was selected because:\n",
    "\n",
    "- It supports **both vector search (embeddings) and lexical search (BM25)**, allowing for **hybrid retrieval**.\n",
    "- It includes **built-in persistence**, meaning stored embeddings can be reused without recomputation.\n",
    "- It allows storing **metadata**, which helps track the source of retrieved documents.\n",
    "\n",
    "This makes ChromaDB a **better choice than FAISS**, which only supports vector search and does not natively store metadata or perform hybrid retrieval.\n",
    "\n",
    "---\n",
    "\n",
    "**Models to Experiment With**\n",
    "| **Model Name** | **Description** |\n",
    "|--------------|----------------|\n",
    "| **GPT-4o-mini** | OpenAI's most advanced language model, capable of high-quality reasoning and text generation. |\n",
    "| **GPT-3.5** | A faster and more cost-effective alternative to GPT-4, useful for real-time applications. |\n",
    "| **Gemini 1.5 Flash** | Optimized for speed and efficiency, suitable for tasks requiring quick responses. |\n",
    "| **Gemini 1.5 Pro** | More powerful than Gemini Flash, designed for complex reasoning and multimodal tasks. |\n",
    "\n",
    "---\n",
    "\n",
    "**Retrieval Methods to Compare**\n",
    "| **Retrieval Method** | **Description** |\n",
    "|--------------------|----------------|\n",
    "| **Embedding-Based Search** | Uses semantic similarity to find relevant documents based on vector representations. |\n",
    "| **BM25 (Lexical Search)** | A keyword-based retrieval method that ranks documents based on term frequency and inverse document frequency. |\n",
    "| **Hybrid Search (BM25 + Embeddings)** | Combines BM25 for exact keyword matching with embeddings for semantic understanding. |\n",
    "| **Re-Ranking (BM25/Embeddings + Ranking Model)** | Uses a second-stage model to refine retrieved results, improving precision for complex queries. |\n",
    "\n",
    "---\n",
    "\n",
    "**Best Embedding Models to Try**\n",
    "| **Embedding Model** | **Description** |\n",
    "|--------------------|----------------|\n",
    "| **OpenAI `text-embedding-ada-002`** | OpenAI's most widely used embedding model, optimized for general-purpose retrieval. |\n",
    "| **Gemini Embeddings** | Google's proprietary embedding model, optimized for retrieval within the Gemini ecosystem. |\n",
    "| **all-MiniLM-L6-v2** | A small, efficient model that balances speed and accuracy for embedding-based retrieval. |\n",
    "| **bge-large-en-v1.5** | A larger embedding model designed for improved retrieval accuracy in dense vector search. |\n",
    "\n",
    "---\n",
    "\n",
    "This setup will allow for a **direct comparison of GPT vs. Gemini** using multiple retrieval techniques and embedding models to determine the best configuration for the given dataset."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "215b0e06-ed4a-44f1-8402-ca5fe841da88",
   "metadata": {
    "tags": []
   },
   "source": [
    "#### Load embeddings"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "3f0e2bb0-9f62-492f-a9a4-88e18fa4a1be",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total Gemini embeddings: 1327\n",
      "Total MiniLM embeddings: 1837\n",
      "Total OpenAI embeddings: 1327\n"
     ]
    }
   ],
   "source": [
    "db_gemini = Chroma(persist_directory=\"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings/chroma_db_gemini\")\n",
    "db_minilm = Chroma(persist_directory=\"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings/chroma_db_minilm\")\n",
    "db_openai = Chroma(persist_directory=\"/Users/catarinasilva/Desktop/Master Thesis/lung_cancer/LLM lung cancer/embedings/chroma_db_openAI\")\n",
    "\n",
    "\n",
    "# Load stored embeddings\n",
    "stored_gemini = load_all_embeddings(db_gemini)\n",
    "stored_minilm = load_all_embeddings(db_minilm)\n",
    "stored_openai = load_all_embeddings(db_openai)\n",
    "\n",
    "# Print count of stored embeddings\n",
    "print(f\"Total Gemini embeddings: {len(stored_gemini['documents'])}\")\n",
    "print(f\"Total MiniLM embeddings: {len(stored_minilm['documents'])}\")\n",
    "print(f\"Total OpenAI embeddings: {len(stored_openai['documents'])}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "c13d2f3b-264a-4e92-8450-8d0326c66a0c",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Gemini Embedding Dimensions: 768\n",
      "MiniLM Embedding Dimensions: 384\n",
      "Open AI Embedding Dimensions: 1536\n"
     ]
    }
   ],
   "source": [
    "# Retrieve a single stored embedding to check dimensions\n",
    "sample_gemini = db_gemini._collection.get(include=[\"embeddings\"], limit=1)\n",
    "sample_minilm = db_minilm._collection.get(include=[\"embeddings\"], limit=1)\n",
    "sample_openai= db_openai._collection.get(include=[\"embeddings\"], limit=1)\n",
    "\n",
    "# Extract the first embedding from each (if available)\n",
    "print(\"Gemini Embedding Dimensions:\", len(sample_gemini[\"embeddings\"][0]))\n",
    "print(\"MiniLM Embedding Dimensions:\", len(sample_minilm[\"embeddings\"][0]))\n",
    "print(\"Open AI Embedding Dimensions:\", len(sample_openai[\"embeddings\"][0]))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5fafa48e-bba9-44c1-bd07-0f17bf536149",
   "metadata": {},
   "source": [
    "### Response Generation"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2f7e1b1a-494a-4be0-b922-83005a1dc551",
   "metadata": {},
   "source": [
    "#### Model response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "536836db-1d57-4465-af79-fd890dcb1874",
   "metadata": {
    "tags": []
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Running test with: gemini embeddings | cosine retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "\n",
      "**AJCC TNM Stage**:\n",
      "- **T Stage**: T1b (tumor size > 3 cm but ≤ 5 cm, no local invasion)\n",
      "- **N Stage**: N3 (metastasis to ipsilateral supraclavicular or contralateral mediastinal lymph nodes)\n",
      "- **M Stage**: M1 (distant metastasis)\n",
      "\n",
      "Based on the AJCC 8th Edition criteria:\n",
      "- The combination of T1b, N3, and M1 categorizes this case as **Stage IV**.\n",
      "\n",
      "**Extensive or Limited Stage Classification**:\n",
      "- **Small Cell Lung Cancer (SCLC)** is classified as **Extensive-Stage SCLC (ES-SCLC)** when there is any distant metastasis (M1). In this case, since M1 is present, the cancer is classified as **ES-SCLC**.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "\n",
      "**Treatment Strategy for Extensive-Stage SCLC**:\n",
      "1. **Systemic Therapy**:\n",
      "   - **First-Line Chemotherapy**: \n",
      "     - **Carboplatin** plus **Etoposide** is the traditional regimen. \n",
      "     - Newer options may include combination regimens like **cisplatin** with **etoposide** depending on patient-specific factors.\n",
      "   - **Immunotherapy** (for eligible patients):\n",
      "     - Consideration of adding **Atezolizumab** or **Durvalumab** to chemotherapy, based on individual patient characteristics and recent advances in clinical trials.\n",
      "\n",
      "2. **Radiation Therapy**:\n",
      "   - **Thoracic Radiation** may be indicated in select patients who respond well to chemotherapy (typically those with limited extrathoracic spread).\n",
      "   - Prophylactic Cranial Irradiation (PCI) may be offered in patients who achieve a complete or near-complete response to initial therapy to prevent potential brain metastases.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "\n",
      "- **Chemotherapy Regimens**:\n",
      "  - **Carboplatin** (AUC 5–6) + **Etoposide** (100 mg/m² on days 1–3) for 4 to 6 cycles.\n",
      "  - Consideration of PCI if the patient responds favorably to treatment.\n",
      "  \n",
      "- **Radiotherapy**:\n",
      "  - **Thoracic Radiation Therapy (TRT)** may be delivered at 45–60 Gy in 1.8–2.0 Gy daily fractions.\n",
      "\n",
      "### 4. Clinical Trial Considerations\n",
      "\n",
      "- Patients may be eligible for clinical trials evaluating novel agents or combinations, including emerging immunotherapies, targeted therapies, or novel radiotherapy fractionation schemes. \n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "\n",
      "- **Symptom Management**: Early integration of palliative care to manage symptoms associated with brain metastases, pain management, and complications like superior vena cava syndrome.\n",
      "- **Supportive Care**: Focus on managing chemotherapy-related toxicities, providing anti-emetics, and ensuring monitoring for potential myelosuppression.\n",
      "\n",
      "### 6. Follow-Up Plan\n",
      "\n",
      "- **Surveillance**: \n",
      "  - Imaging with CT scans of the chest and abdomen every 2–3 months during the first year to monitor response to therapy and detect any recurrence.\n",
      "  - Follow-up evaluations focused on assessing therapy-related toxicities and overall health.\n",
      "\n",
      "**Monitoring needs**: \n",
      "- Regular blood counts to assess for myelosuppression, particularly monitoring neutrophil counts due to the risk of chemotherapy-induced febrile neutropenia.\n",
      "\n",
      "### Summary\n",
      "\n",
      "- **Clinical Stage**: IV (Extensive-Stage SCLC)\n",
      "- **Treatment Plan**: Chemotherapy with Carboplatin and Etoposide, potential inclusion of immunotherapy, and consideration for radiation therapy based on response.\n",
      "- **Clinical Trials**: Opportunities for participation in trials evaluating new therapeutic options should be discussed.\n",
      "- **Palliative Care**: Essential for symptom management, particularly with potential complications from cancer progression.\n",
      "- **Follow-Up**: Regular imaging and supportive care assessments to manage treatment-related effects.\n",
      "\n",
      "\n",
      "Running test with: gemini embeddings | cosine retrieval | gemini LLM\n",
      "Response:\n",
      "### Final Structured Output\n",
      "\n",
      "1.  **Clinical Stage**:\n",
      "    *   AJCC TNM Stage: T1b, N3, M1\n",
      "    *   Stage IV\n",
      "    *   Extensive-Stage SCLC (ES-SCLC)\n",
      "\n",
      "2.  **Treatment Plan**:\n",
      "    The patient has Extensive-Stage SCLC (ES-SCLC), the treatment plan will focus on systemic therapy.\n",
      "\n",
      "    *   **Systemic Therapy**: Chemotherapy with or without immunotherapy is the primary treatment approach.\n",
      "\n",
      "3.  **Therapeutic Modalities**:\n",
      "    *   **Chemotherapy Regimens**:\n",
      "        *   First-line chemotherapy typically involves combinations of drugs, with the most common being **etoposide + cisplatin or carboplatin**.\n",
      "        *   If SCLC worsens or returns, single-agent chemotherapy may be considered.\n",
      "    *   **Radiation Therapy**: Thoracic radiation may be considered.\n",
      "    *   **Prophylactic Cranial Irradiation (PCI)**: Consider PCI or MRI surveillance.\n",
      "\n",
      "4.  **Clinical Trial Considerations**:\n",
      "    *   Given the challenges in treating relapsed or refractory SCLC, participation in clinical trials is a good option for the patient.\n",
      "\n",
      "5.  **Palliative and Supportive Care**:\n",
      "    *   **Symptom Management**: Focus on managing symptoms related to brain metastases, superior vena cava syndrome, and paraneoplastic syndromes.\n",
      "    *   **Early Integration of Palliative Services**: It is essential to integrate palliative services early in the treatment course to address symptom burden and enhance quality of life.\n",
      "\n",
      "6.  **Follow-Up Plan**:\n",
      "    *   Monitor chemotherapy-related toxicities and manage side effects to optimize treatment tolerance and adherence.\n",
      "    *   Regular follow-up appointments, including CT scans, will be scheduled to monitor treatment response and detect any signs of recurrence. The frequency of these appointments will be determined by the oncologist based on treatment response and individual patient factors.\n",
      "\n",
      "\n",
      "\n",
      "Running test with: gemini embeddings | bm25 retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "\n",
      "**Clinical TNM Stage**: T1b, N3, M1\n",
      "\n",
      "- **T1b** means the primary tumor is >3 cm but ≤4 cm and has not grown into more distant structures.\n",
      "- **N3** indicates involvement of contralateral (opposite side) lymph nodes or metastasis to lymph nodes above the clavicle. \n",
      "- **M1** means that there is distant metastasis to another site in the body.\n",
      "\n",
      "According to the AJCC 8th Edition for Small Cell Lung Carcinoma, when the M stage is M1, it classifies the cancer as **Stage IV**.\n",
      "\n",
      "### Classification: \n",
      "For Small Cell Lung Cancer (SCLC), based on the classification scheme:\n",
      "- **Extensive-Stage SCLC (ES-SCLC)**: This classification is applied if the cancer has spread beyond the primary site and regional lymph nodes. Given the presence of distant metastasis (M1), this patient’s cancer is classified as **Extensive-Stage SCLC**.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "\n",
      "#### Treatment Strategy for ES-SCLC\n",
      "\n",
      "**First-Line Systemic Therapy:**\n",
      "- **Chemotherapy Regimen**: Patients with ES-SCLC typically receive chemotherapy as the main treatment approach. The standard regimen includes:\n",
      "  - **Etoposide**: 100 mg/m² IV on days 1-3.\n",
      "  - **Cisplatin**: 80 mg/m² IV on day 1 or **Carboplatin** (AUC 5-6) on day 1.\n",
      "  \n",
      "The chemotherapy is often given every 21 days for 4-6 cycles but may be adjusted based on patient tolerance and disease response. \n",
      "\n",
      "**Radiation Therapy:**\n",
      "- **Thoracic Radiation Therapy (TRT)**: Consider TRT in selected patients who respond to initial chemotherapy, which may help in controlling symptoms and local disease spread.\n",
      "- **Prophylactic Cranial Irradiation (PCI)**: Recommended for patients with a complete or significant response to initial therapy to reduce the risk of brain metastases.\n",
      "\n",
      "#### Considerations for Older Adults (≥70 years):\n",
      "- Given the patient is 72 years old, treatment intensity should be evaluated carefully. The clinician should assess:\n",
      "  - **Performance Status**: Adjust chemotherapy regimens if the patient has significant comorbidities leading to poor performance status.\n",
      "  - **Hematologic Toxicities**: Older patients are at risk for higher toxicity; consider dose reduction strategies depending on renal function and therapeutic tolerance.\n",
      "\n",
      "### 3. Clinical Trial Considerations\n",
      "- Enrollment in clinical trials might be considered as there are emerging therapies, including immunotherapy (e.g., combining chemotherapy with agents such as **durvalumab**) or novel agents being studied in the setting of extensive-stage disease.\n",
      "\n",
      "### 4. Palliative and Supportive Care\n",
      "- Early integration of **Palliative Care** services is recommended for symptom management related to metastasis, such as dyspnea or pain.\n",
      "- **Symptom Management Strategies**: Address common symptoms in ES-SCLC, including nausea caused by chemotherapy and management of potential complications related to metastasis (e.g., brain metastases).\n",
      "\n",
      "### 5. Follow-Up and Surveillance\n",
      "- After completion of initial treatment, a follow-up schedule should be established:\n",
      "  - **CT Scans**: Suggested every 3-4 months to monitor for recurrence or new metastases.\n",
      "  - **Symptom Assessments**: Regular assessments of treatment-related toxicities, such as hematologic side effects, should occur at each visit.\n",
      "\n",
      "In summary, this patient’s lung cancer is classified as **Stage IV, Extensive-Stage SCLC**. The recommended treatment plan includes combination chemotherapy with potential follow-up radiotherapy and suitable supportive measures, particularly considering her age and overall health.\n",
      "\n",
      "\n",
      "Running test with: gemini embeddings | bm25 retrieval | gemini LLM\n",
      "Response:\n",
      "### 1. Clinical Stage:\n",
      "\n",
      "Based on the provided information:\n",
      "*   **T Stage:** T1b\n",
      "*   **N Stage:** N3\n",
      "*   **M Stage:** M1\n",
      "\n",
      "According to the TNM classification, this patient has **Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**. The presence of distant metastasis (M1) automatically classifies the cancer as extensive stage, regardless of T and N stages.\n",
      "\n",
      "### 2. Treatment Plan:\n",
      "\n",
      "Given the diagnosis of Extensive-Stage SCLC (ES-SCLC), the primary treatment goal is systemic therapy.\n",
      "\n",
      "*   **Systemic Therapy:** The recommended first-line treatment is chemotherapy.\n",
      "\n",
      "    *   **Chemotherapy Regimen:** The standard chemotherapy regimen typically involves a combination of agents, most commonly **etoposide** plus either **cisplatin** or **carboplatin**.\n",
      "*   **Thoracic Radiation:** Thoracic radiation should be considered in patients who respond to systemic chemotherapy.\n",
      "*   **Prophylactic Cranial Irradiation (PCI) or MRI Surveillance:**  Following systemic therapy, PCI should be considered for patients who have had a response to chemotherapy, with MRI surveillance as an alternative option.\n",
      "\n",
      "### 3. Therapeutic Modalities:\n",
      "\n",
      "*   **Chemotherapy:**\n",
      "    *   Etoposide + Cisplatin\n",
      "    *   Etoposide + Carboplatin\n",
      "*   **Radiotherapy:**\n",
      "    *   Thoracic Radiation Therapy (TRT)\n",
      "    *   Prophylactic Cranial Irradiation (PCI)\n",
      "\n",
      "### 4. Clinical Trial Considerations:\n",
      "\n",
      "Patients with ES-SCLC should be evaluated for potential enrollment in clinical trials. Current areas of investigation include:\n",
      "\n",
      "*   Immunotherapy combinations\n",
      "*   Novel chemotherapy agents\n",
      "*   Modified radiotherapy fractionation schedules\n",
      "\n",
      "### 5. Palliative and Supportive Care:\n",
      "\n",
      "Given the potential for metastatic disease in ES-SCLC, palliative care should be integrated early. This includes:\n",
      "\n",
      "*   **Symptom Management:** Addressing symptoms related to brain metastases (e.g., corticosteroids, local radiation), superior vena cava syndrome (e.g., steroids, endovascular stent placement, radiation), and paraneoplastic syndromes (specific treatment depends on the syndrome).\n",
      "*   **Early Integration of Palliative Services:**  Involving palliative care specialists to optimize symptom control, provide psychosocial support, and assist with advance care planning.\n",
      "\n",
      "### 6. Follow-Up Plan:\n",
      "\n",
      "Following treatment for ES-SCLC, the recommended follow-up includes:\n",
      "\n",
      "*   **Regular Monitoring:** Frequent follow-up appointments should be scheduled (e.g., every 3-6 months for the first 2 years, then every 6-12 months).\n",
      "*   **CT Scans:** Regular CT scans of the chest and abdomen to monitor for recurrence.\n",
      "*   **Neurological Assessment:** Monitor for signs and symptoms of brain metastases.\n",
      "*   **Chemotherapy-Related Toxicities:** Monitoring for long-term complications from chemotherapy (e.g., neuropathy, cardiac dysfunction).\n",
      "\n",
      "\n",
      "\n",
      "Running test with: gemini embeddings | combined retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "\n",
      "Based on the patient data provided, the TNM classification indicates:\n",
      "- **Tumor (T)**: T1b (the tumor is larger than 3 cm but no larger than 4 cm)\n",
      "- **Lymph Node (N)**: N3 (metastasis to mediastinal and/or contralateral lymph nodes)\n",
      "- **Metastasis (M)**: M1 (metastasis to distant organs)\n",
      "\n",
      "According to the AJCC 8th Edition staging criteria for Small Cell Lung Cancer (SCLC), the classification for this case is:\n",
      "- **Stage IV**\n",
      "  \n",
      "Given the patient's staging information, we further classify it as **Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**. In SCLC, extensive stage is typically characterized by either the presence of distant metastases (like in this case with M1) or significant local spread that exceeds the radiation field.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "\n",
      "For **Extensive-Stage SCLC** (ES-SCLC), the following evidence-based treatment options are recommended per clinical guidelines:\n",
      "\n",
      "- **Systemic Therapy**:\n",
      "  - **Chemotherapy regimen**: \n",
      "    - **Etoposide + Carboplatin or Cisplatin**: This is the standard first-line treatment for ES-SCLC.\n",
      "  \n",
      "- **Radiotherapy**:\n",
      "  - **Thoracic Radiation Therapy (TRT)**: \n",
      "    - Consider using TRT in patients who exhibit a good response to first-line chemotherapy with significant disease burden improvement.\n",
      "  \n",
      "- **Prophylactic Cranial Irradiation (PCI)**: \n",
      "  - Consider PCI for patients who have a complete or near-complete response to initial chemotherapy to prevent brain metastases. \n",
      "  - Note that PCI is generally recommended if the patient shows good prognosis and completion of initial therapy.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "\n",
      "- **Chemotherapy Regimens**: \n",
      "  - **Etoposide and Carboplatin/Cisplatin** are encouraged according to the guidelines.\n",
      "  \n",
      "- **Radiotherapy Modalities**:\n",
      "  - **Thoracic Radiation Therapy (TRT)** if indicated based on the response to chemotherapy.\n",
      "  - **Prophylactic Cranial Irradiation (PCI)** as mentioned above, after assessing for potential benefits.\n",
      "  \n",
      "### 4. Clinical Trial Considerations\n",
      "\n",
      "Ongoing clinical trials for patients with ES-SCLC may explore:\n",
      "- Novel systemic agents, including immunotherapy and targeted therapies, as consolidation therapies.\n",
      "- Advanced radiation techniques or combinations thereof.\n",
      "  \n",
      "It is advisable to discuss potential participation in clinical trials focusing on these areas as they may offer additional treatment options not yet widely available.\n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "\n",
      "- **Symptom Management**: This includes relief of symptoms related to:\n",
      "  - Brain metastases (e.g., headaches, seizures).\n",
      "  - Superior vena cava syndrome (if present).\n",
      "  - Paraneoplastic syndromes (e.g., hypercalcemia).\n",
      "  \n",
      "- **Integration**: \n",
      "  - Palliative care should be integrated early, particularly considering age and performance status, to enhance quality of life and address psychosocial needs.\n",
      "\n",
      "### 6. Follow-Up Plan \n",
      "\n",
      "- **Surveillance**:\n",
      "  - Schedule follow-ups based on the treatment response, typically every 1-3 months after completion of initial therapy.\n",
      "  - **Imaging**: \n",
      "    - Consider chest CT scans and/or brain MRI surveillance, particularly for those at risk for neurological metastases, based on responses or symptoms.\n",
      "  \n",
      "- **Monitoring**:\n",
      "  - Closely monitor for chemotherapy-related toxicities, including hematologic parameters and functional status.\n",
      "  - Address any concerns or changes in symptoms proactively.\n",
      "\n",
      "By adhering to these guidelines and recommendations, the multidisciplinary care team can effectively manage the treatment of this patient's extensive-stage small cell lung cancer while optimizing the quality of her life.\n",
      "\n",
      "\n",
      "Running test with: gemini embeddings | combined retrieval | gemini LLM\n",
      "Response:\n",
      "### 1. Clinical Stage:\n",
      "\n",
      "*   **AJCC TNM Stage:** T1b, N3, M1\n",
      "*   Based on the TNM classification, this patient has **Extensive-Stage SCLC (ES-SCLC)**. SCLC is classified into two stages: Limited and Extensive. The presence of distant metastasis (M1) automatically classifies the patient as having Extensive-Stage disease.\n",
      "\n",
      "### 2. Treatment Plan:\n",
      "\n",
      "Given the patient's diagnosis of Extensive-Stage SCLC (ES-SCLC), the primary treatment strategy is systemic therapy.\n",
      "\n",
      "*   **Systemic Therapy:** The recommended first-line treatment is **chemotherapy**.\n",
      "    *   **Chemotherapy Regimens**: Chemotherapy regimens should include **etoposide** in combination with either **cisplatin or carboplatin**.\n",
      "\n",
      "*   **Thoracic Radiation Therapy (TRT):** The role of consolidative thoracic radiation in ES-SCLC remains controversial. Consider **thoracic radiation** in responders to initial chemotherapy.\n",
      "\n",
      "*   **Prophylactic Cranial Irradiation (PCI):** Given the propensity for SCLC to metastasize to the brain, **prophylactic cranial irradiation (PCI)** should be considered for patients who have responded to initial chemotherapy. An alternative to PCI is MRI surveillance.\n",
      "\n",
      "### 3. Therapeutic Modalities:\n",
      "\n",
      "*   **Chemotherapy:**\n",
      "    *   Etoposide + Cisplatin\n",
      "    *   Etoposide + Carboplatin\n",
      "*   **Radiotherapy:**\n",
      "    *   Thoracic Radiation Therapy (TRT)\n",
      "    *   Prophylactic Cranial Irradiation (PCI)\n",
      "\n",
      "### 4. Clinical Trial Considerations:\n",
      "\n",
      "*   Based on the current disease state and patient factors, enrollment in a **clinical trial** should be considered. Areas of active investigation include immunotherapy combinations, novel radiotherapy fractionation schedules, and new targeted agents.\n",
      "\n",
      "### 5. Palliative and Supportive Care:\n",
      "\n",
      "*   **Symptom Management:** Comprehensive symptom management is crucial. Specific interventions should address:\n",
      "    *   **Brain Metastases:** Manage neurological symptoms with corticosteroids, whole-brain radiation therapy, or stereotactic radiosurgery.\n",
      "    *   **Superior Vena Cava Syndrome:** Address SVC syndrome with corticosteroids and/or endovascular stenting.\n",
      "    *   **Paraneoplastic Syndromes:** Treat paraneoplastic syndromes (e.g., SIADH, Lambert-Eaton) with appropriate medical management.\n",
      "*   **Early Palliative Care Integration:** Early integration of palliative care services is essential to optimize symptom control, improve quality of life, and facilitate informed decision-making.\n",
      "\n",
      "### 6. Follow-Up Plan:\n",
      "\n",
      "*   **Surveillance:** Follow-up is critical to monitor for recurrence and treatment-related toxicities.\n",
      "    *   **Frequency:** Follow-up should occur every 3-6 months for the first 2 years, then every 6-12 months for the next 3 years, and then annually.\n",
      "    *   **Imaging:** CT scans of the chest and abdomen should be performed every 3-6 months for the first 2 years to monitor for recurrence.\n",
      "*   **Monitoring:**\n",
      "    *   Monitor for chemotherapy-related toxicities such as myelosuppression, neuropathy, and cardiac dysfunction.\n",
      "    *   Assess for signs and symptoms of disease recurrence (e.g., cough, dyspnea, weight loss, bone pain, neurological deficits).\n",
      "\n",
      "\n",
      "\n",
      "Running test with: minilm embeddings | cosine retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### Final Structured Output\n",
      "\n",
      "1. **Clinical Stage**:\n",
      "   - Based on the provided TNM stage:\n",
      "     - **Tumor (T)**: T1b (which indicates a tumor size of >3 cm but ≤5 cm)\n",
      "     - **Lymph Node (N)**: N3 (indicating involvement of supraclavicular and/or contralateral lymph nodes)\n",
      "     - **Metastasis (M)**: M1 (indicating the presence of metastasis)\n",
      "     \n",
      "   Following the AJCC 8th Edition staging system for Small Cell Lung Cancer (SCLC):\n",
      "   - The overall classification is **Extensive-Stage SCLC (ES-SCLC)** because the presence of M1 confirms that the cancer has metastasized beyond the lung and regional nodes. The classification criteria for ES-SCLC include tumors with any T, any N, and M1.\n",
      "\n",
      "2. **Treatment Plan**:\n",
      "   - For **Extensive-Stage SCLC**:\n",
      "     - **Systemic Therapy**: Recommended chemotherapy regimen includes **carboplatin + etoposide**, typically administered over **4-6 cycles**. \n",
      "     - **Immunotherapy**: Consideration of **atezolizumab** or **durvalumab** may be included as part of treatment, especially in combination if the clinical response is favorable.\n",
      "     - **Radiation Therapy**: Thoracic radiation therapy (TRT) is indicated for patients demonstrating a clinical response to chemotherapy. Also consider prophylactic cranial irradiation (PCI), particularly in those achieving a complete/near-complete response.\n",
      "     - Alternatives may include single-agent chemotherapy or lower-intensity regimens due to age and potential comorbidities.\n",
      "\n",
      "3. **Therapeutic Modalities**:\n",
      "   - Chemotherapy:\n",
      "     - **Carboplatin** in combination with **etoposide**\n",
      "   - Immunotherapy (if indicated):\n",
      "     - **Atezolizumab** or **Durvalumab**\n",
      "   - Radiation therapy modalities:\n",
      "     - **Thoracic Radiation Therapy (TRT)**\n",
      "     - **Prophylactic Cranial Irradiation (PCI)** as indicated.\n",
      "\n",
      "4. **Clinical Trial Considerations**:\n",
      "   - There may be ongoing clinical trials evaluating new combinations of chemotherapy, emerging immunotherapy agents, and novel mechanisms of action in ES-SCLC. Referral to clinical trials should be considered based on institutional availability and patient eligibility criteria.\n",
      "\n",
      "5. **Palliative and Supportive Care**:\n",
      "   - The integration of palliative care is crucial for symptom management, particularly with symptoms related to brain metastases, respiratory distress, or SVC syndrome. Establishing early palliative services can enhance patient quality of life.\n",
      "   - Assess for therapeutic interventions to manage chemotherapy-related side effects, such as antiemetics for nausea and antibiotics for infection prophylaxis.\n",
      "\n",
      "6. **Follow-Up Plan**:\n",
      "   - Regular follow-up after treatment should involve:\n",
      "     - **CT imaging** every 3-4 months for recurrence monitoring.\n",
      "     - Evaluation for chemotherapy-related toxicities, specifically hematologic parameters such as complete blood counts (CBC) to watch for neutropenia or thrombocytopenia.\n",
      "     - Clinical assessments focusing on symptom control and quality of life measures should also be addressed at each visit. \n",
      "\n",
      "This comprehensive approach should be aligned with current clinical guidelines, ensuring timely interventions and modifications based on the patient's clinical course and treatment response.\n",
      "\n",
      "\n",
      "Running test with: minilm embeddings | cosine retrieval | gemini LLM\n",
      "Response:\n",
      "### Clinical Stage\n",
      "Based on the AJCC 8th Edition TNM staging system, the patient's cancer is staged as:\n",
      "- **Stage IV Small Cell Lung Cancer (SCLC)**\n",
      "- **Extensive-Stage SCLC (ES-SCLC)**\n",
      "\n",
      "This classification is based on the following:\n",
      "- T1b: Tumor size is > 1 cm but ≤ 2 cm.\n",
      "- N3: Cancer has spread to contralateral mediastinal or hilar lymph nodes, or to any supraclavicular or scalene lymph nodes.\n",
      "- M1: Distant metastasis is present.\n",
      "The presence of distant metastasis (M1) automatically classifies the SCLC as Extensive-Stage.\n",
      "\n",
      "### Treatment Plan\n",
      "Given the diagnosis of Extensive-Stage SCLC (ES-SCLC), the treatment plan should focus on systemic therapy.\n",
      "\n",
      "1.  **Systemic Therapy:**\n",
      "    *   The primary treatment modality is combination chemotherapy. According to the American Cancer Society guidelines, first-line chemotherapy combinations often include:\n",
      "        *   Etoposide + Cisplatin or Carboplatin\n",
      "\n",
      "2.  **Thoracic Radiation:**\n",
      "    *   Consider thoracic radiation therapy (TRT) for patients who respond to initial chemotherapy.\n",
      "\n",
      "3.  **Prophylactic Cranial Irradiation (PCI):**\n",
      "    *   PCI or MRI surveillance should be considered for patients who achieve a response to systemic therapy.\n",
      "\n",
      "4.  **Maintenance Immunotherapy:**\n",
      "    *   Per clinical guidelines, maintenance immunotherapy with a single immunotherapy drug may be considered for patients who have a good response to initial chemotherapy or have had no worsening of their cancer.\n",
      "\n",
      "5.  **Age Considerations**\n",
      "    *   Given the patient's age of 72, treatment tolerance should be carefully evaluated based on comorbidities and performance status. Adjust treatment intensity accordingly.\n",
      "    *   Older adults may have a higher risk of hematologic toxicity and treatment-related mortality with standard chemoradiotherapy.\n",
      "    *   Supportive care, dose-reduction strategies, or monotherapy may be considered if clinically indicated.\n",
      "\n",
      "### Therapeutic Modalities\n",
      "- Chemotherapy: Etoposide + Cisplatin or Carboplatin\n",
      "- Radiotherapy: Thoracic Radiation Therapy (TRT), Prophylactic Cranial Irradiation (PCI)\n",
      "\n",
      "### Clinical Trial Considerations\n",
      "- Patients with ES-SCLC may be candidates for clinical trials investigating novel immunotherapy combinations, radiotherapy fractionation, or targeted agents.\n",
      "\n",
      "### Palliative and Supportive Care\n",
      "- Early integration of palliative care is recommended to manage symptoms associated with ES-SCLC.\n",
      "- Address symptom management for potential complications such as brain metastases and paraneoplastic syndromes.\n",
      "\n",
      "### Follow-Up Plan\n",
      "- Regular follow-up is essential to monitor treatment response and detect recurrence.\n",
      "- Follow-up schedule should include:\n",
      "    *   Regular physical exams.\n",
      "    *   Imaging studies: CT scans to monitor for recurrence.\n",
      "    *   Monitoring for chemotherapy-related toxicities.\n",
      "\n",
      "\n",
      "\n",
      "Running test with: minilm embeddings | bm25 retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "- **AJCC TNM Stage**: \n",
      "  - **T**: T1b (tumor size 3-5 cm, localized)\n",
      "  - **N**: N3 (metastasis to supraclavicular or contralateral nodes)\n",
      "  - **M**: M1 (distant metastasis)\n",
      "  \n",
      "Given the tumor's characteristics and the presence of N3 involvement alongside M1 metastasis, this corresponds to:\n",
      "\n",
      "- **Stage IV**: This stage reflects widely disseminated disease.\n",
      "\n",
      "- **Extensive-Stage SCLC (ES-SCLC)**: The presence of distant metastasis and local lymph node involvement indicates that the cancer cannot be effectively treated with local modalities alone and is classified as ES-SCLC. This classification is supported by guidelines indicating that SCLC is typically classified as either limited stage or extensive stage based on the extent of disease spread. \n",
      "\n",
      "### 2. Treatment Plan\n",
      "\n",
      "#### Extensive-Stage Small Cell Lung Cancer (ES-SCLC)\n",
      "\n",
      "**Systemic Therapy**:\n",
      "- **First Line Treatment**: \n",
      "  - **Chemotherapy**: \n",
      "    - *Carboplatin* (AUC 5–6) combined with *etoposide* (100 mg/m² on days 1-3, every 21 days) is recommended as a first-line regimen according to established guidelines.\n",
      "  - **Immunotherapy**: \n",
      "    - Adding *atezolizumab* or *durvalumab*, when clinically applicable, is supported based on recent studies showing improved outcomes for ES-SCLC patients.\n",
      "\n",
      "**Radiation Therapy**:\n",
      "- **Thoracic Radiation**: Considered in select cases where there is a good initial response to chemotherapy, it facilitates local control.\n",
      "- **Prophylactic Cranial Irradiation (PCI)**: Recommended for patients who respond well to initial treatment and have good performance status, as it can reduce the risk of brain metastases.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "\n",
      "- **Chemotherapeutic Agents**:\n",
      "  - Etoposide + Carboplatin\n",
      "- **Immunotherapy**:\n",
      "  - Atezolizumab or Durvalumab\n",
      "- **Radiation Therapy**:\n",
      "  - Thoracic Radiotherapy\n",
      "  - Prophylactic Cranial Irradiation\n",
      "\n",
      "### 4. Clinical Trial Considerations\n",
      "\n",
      "Given the extensive-stage classification, the patient may also be eligible for:\n",
      "- Immunotherapy trials that explore novel agents beyond standard chemotherapy.\n",
      "- Trials assessing various radiation fractionation regimes or the addition of targeted therapies on top of standard treatments.\n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "\n",
      "- **Symptom Management**: Address symptoms related to metastasis (e.g., dyspnea, cough, pain).\n",
      "- **Early Integration of Palliative Care**: Involvement of palliative care services should begin promptly to optimize quality of life, especially given the patient’s age and potentially higher comorbidity risk.\n",
      "  \n",
      "### 6. Follow-Up Plan\n",
      "\n",
      "- **Surveillance**:\n",
      "  - Follow-up CT scans every 2–3 months during the first year, then biannually, to monitor for recurrence or progression.\n",
      "  - Regular evaluations for treatment-related toxicities, particularly for hematologic effects from chemotherapy.\n",
      "  \n",
      "This structured treatment plan aligns with current clinical guidelines and literature focused on the management of extensive-stage SCLC, aiming to balance therapeutic efficacy with quality of life considerations.\n",
      "\n",
      "\n",
      "Running test with: minilm embeddings | bm25 retrieval | gemini LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "\n",
      "Based on the provided information:\n",
      "- **T Stage:** T1b\n",
      "- **N Stage:** N3\n",
      "- **M Stage:** M1\n",
      "\n",
      "Using the AJCC 8th Edition TNM staging system, this patient's SCLC is classified as **Stage IV**. The presence of distant metastasis (M1) automatically indicates Stage IV disease. SCLC is also classified into two stages which include limited and extensive stage. Due to the presence of metastasis it's an extensive stage. The patient has **Extensive-Stage SCLC (ES-SCLC)**.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "\n",
      "Given the diagnosis of Extensive-Stage SCLC (ES-SCLC), the primary treatment approach is systemic therapy.\n",
      "\n",
      "*   **Systemic Therapy:** The recommended first-line chemotherapy regimen is:\n",
      "    *   **Etoposide** plus **Cisplatin** or **Carboplatin**.\n",
      "\n",
      "*   **Thoracic Radiation:** For patients who demonstrate a response to chemotherapy, thoracic radiation therapy (TRT) should be considered to consolidate the response.\n",
      "\n",
      "*   **Prophylactic Cranial Irradiation (PCI) or MRI Surveillance:** Following initial treatment, PCI should be considered for patients who achieve a complete or near-complete response. If PCI is not administered, regular MRI surveillance of the brain should be performed to monitor for brain metastases.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "\n",
      "*   **Chemotherapy:**\n",
      "    *   **Etoposide**\n",
      "    *   **Cisplatin** or **Carboplatin**\n",
      "*   **Radiotherapy:**\n",
      "    *   **Thoracic Radiation Therapy (TRT)**\n",
      "    *   **Prophylactic Cranial Irradiation (PCI)**\n",
      "*   **Immunotherapy:**\n",
      "    *   **Durvalumab** can be considered as maintenance therapy in patients who have not progressed after first-line platinum-based chemotherapy.\n",
      "\n",
      "### 4. Clinical Trial Considerations\n",
      "\n",
      "Patients with ES-SCLC may be eligible for clinical trials evaluating novel therapeutic approaches, including:\n",
      "\n",
      "*   New immunotherapy combinations.\n",
      "*   Novel chemotherapy regimens.\n",
      "*   Targeted therapies based on molecular profiling.\n",
      "*   Alternative radiotherapy fractionation schedules.\n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "\n",
      "*   **Symptom Management:** Comprehensive palliative care should be integrated early in the treatment course to manage symptoms such as:\n",
      "    *   Brain metastases: Corticosteroids, whole-brain radiation therapy (WBRT), or stereotactic radiosurgery (SRS) for limited metastases.\n",
      "    *   Superior Vena Cava Syndrome (SVCS): Endovascular stenting or radiation therapy.\n",
      "    *   Paraneoplastic Syndromes: Management of specific syndromes (e.g., SIADH) with appropriate medications.\n",
      "*   **Supportive Care:** Address nutritional support, pain management, and psychosocial support to improve quality of life.\n",
      "\n",
      "### 6. Follow-Up Plan\n",
      "\n",
      "*   **Surveillance:** After completion of initial treatment, the patient should undergo regular follow-up evaluations.\n",
      "    *   **Frequency:** Every 3-6 months for the first 2 years, then every 6-12 months.\n",
      "    *   **Imaging:** CT scans of the chest and abdomen to monitor for recurrence. MRI of the brain should be considered if PCI was not administered initially.\n",
      "*   **Monitoring:** Closely monitor for chemotherapy-related toxicities and late effects.\n",
      "*   **Survivorship Care:** Provide comprehensive survivorship care, including smoking cessation support, management of comorbidities, and psychosocial support.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "Running test with: minilm embeddings | combined retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "\n",
      "Using the AJCC 8th Edition staging system for Small Cell Lung Cancer (SCLC), we analyze the patient's information:\n",
      "\n",
      "- **Tumor Stage (T)**: T1b - This indicates a tumor size of more than 3 cm but not exceeding 5 cm.\n",
      "- **Lymph Node Stage (N)**: N3 - This indicates involvement of contralateral supraclavicular or scalene lymph nodes (more extensive nodal involvement).\n",
      "- **Metastasis Stage (M)**: M1 - This indicates the presence of distant metastasis.\n",
      "\n",
      "Combining these parameters according to the AJCC SCLC staging criteria, this patient is classified as having **Stage IV SCLC**.\n",
      "\n",
      "Further classification using limited/extensive stage definitions establishes that the patient has **Extensive-Stage Small Cell Lung Cancer (ES-SCLC)** as the presence of distant metastatic disease (M1) indicates advanced disease.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "\n",
      "#### Evidence-Based Treatment Strategy for ES-SCLC:\n",
      "\n",
      "1. **Systemic Chemotherapy**:\n",
      "   - **First-line treatment**: The recommended chemotherapy regimen for extensive-stage SCLC includes **carboplatin** and **etoposide** or **cisplatin** and **etoposide** administered every 21 days for 4-6 cycles.\n",
      "  \n",
      "2. **Thoracic Radiation Therapy (TRT)**:\n",
      "   - **Indication**: Considered in patients who respond well to systemic chemotherapy, particularly if there is significant tumor burden in the thorax.\n",
      "\n",
      "3. **Prophylactic Cranial Irradiation (PCI)**:\n",
      "   - **Implementation**: After achieving a complete or partial response to initial treatment, PCI should be considered to reduce the risk of brain metastases.\n",
      "\n",
      "4. **Additional Considerations**:\n",
      "   - **Clinical Trials**: Investigation into the use of novel agents or combinations, particularly those involving immunotherapy agents such as immune checkpoint inhibitors (e.g., nivolumab or atezolizumab), could be considered given the patient's advanced age and ES-SCLC status.\n",
      "   - Regular reassessment of performance status and tolerability to chemotherapy is essential, especially because the patient is an older adult.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "\n",
      "- **Chemotherapy Agents**:\n",
      "  - **First-Line**: Carboplatin + Etoposide or Cisplatin + Etoposide\n",
      "- **Radiotherapy**:\n",
      "  - **Thoracic Radiation Therapy (TRT)**\n",
      "  - **Prophylactic Cranial Irradiation (PCI)** post-response.\n",
      "  \n",
      "### 4. Clinical Trial Considerations\n",
      "\n",
      "Enrolling in clinical trials could provide access to potential new therapies or combinations that may improve outcomes. Trials investigating the use of immunotherapy agents or novel combination chemotherapies are relevant options for this patient with ES-SCLC.\n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "\n",
      "Palliative care should be integrated early in the treatment approach, focusing on the following aspects:\n",
      "- **Symptom Management**: Address symptoms such as dyspnea, pain, and treatment-related side effects.\n",
      "- **Coordination of Care**: Supportive services should be involved to manage complications associated with brain metastases, superior vena cava syndrome, and psychosocial aspects of cancer management.\n",
      "\n",
      "### 6. Follow-Up Plan\n",
      "\n",
      "- **Follow-Up Strategy**:\n",
      "  - **Frequency**: Follow-up visits should occur every 1-3 months depending on treatment response and any symptomatology.\n",
      "  - **Monitoring**: Regular CT scans may be necessary to assess tumor response, and surveillance for chemotherapy-related toxicities must be performed.\n",
      "  - **Survivorship Care**: Close attention to the management of late effects of treatment and ongoing supportive care needs.\n",
      "\n",
      "In summary, this patient's SCLC is classified as **Extensive-Stage**, and the treatment plan comprises systemic chemotherapy, possible TRT in responders, PCI, and supportive care integration to manage any symptoms or complications effectively.\n",
      "\n",
      "\n",
      "Running test with: minilm embeddings | combined retrieval | gemini LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "Based on the provided information and the AJCC 8th Edition TNM staging system, the patient's cancer stage is:\n",
      "\n",
      "*   **TNM Stage:** T1b N3 M1\n",
      "*   Given the presence of distant metastasis (M1), this patient has **Extensive-Stage SCLC (ES-SCLC)**.\n",
      "\n",
      "### 2. Treatment Plan (ES-SCLC)\n",
      "The patient has Extensive-Stage SCLC (ES-SCLC). Therefore, the treatment plan should follow guidelines for ES-SCLC.\n",
      "\n",
      "*   **Systemic Therapy:**\n",
      "    *   The recommended initial treatment is systemic therapy, which typically includes chemotherapy.\n",
      "    *   The standard chemotherapy regimen is **etoposide + cisplatin or carboplatin**.\n",
      "\n",
      "*   **Thoracic Radiation:**\n",
      "    *   Consider thoracic radiation for patients who demonstrate a response to initial chemotherapy.\n",
      "\n",
      "*   **Prophylactic Cranial Irradiation (PCI) or MRI Surveillance:**\n",
      "    *   After completion of initial treatment, **PCI** may be considered, or alternatively, **MRI surveillance** of the brain.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "\n",
      "*   **Chemotherapy:** Etoposide in combination with either cisplatin or carboplatin.\n",
      "*   **Radiotherapy:** Thoracic radiation therapy (TRT), Prophylactic Cranial Irradiation (PCI).\n",
      "*   **Immunotherapy:**\n",
      "    *   The document mentions the use of immunotherapy with durvalumab in the context of Limited-Stage SCLC consolidation. There is no information about immunotherapy regimens for ES-SCLC, so this cannot be incorporated into the treatment plan.\n",
      "\n",
      "### 4. Clinical Trial Considerations\n",
      "*   Ongoing clinical trials are investigating immunotherapy, radiotherapy fractionation, and novel agents. The patient should be evaluated for eligibility in relevant clinical trials based on their disease state and individual factors.\n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "*   **Symptom Management:**\n",
      "    *   Address symptoms related to brain metastases, superior vena cava syndrome, and paraneoplastic syndromes.\n",
      "*   **Early Integration of Palliative Services:**\n",
      "    *   Integrate palliative care early to manage symptoms, improve quality of life, and support the patient and their family.\n",
      "\n",
      "### 6. Follow-Up Plan\n",
      "*   **Surveillance:**\n",
      "    *   Regular follow-up should include monitoring for recurrence and chemotherapy-related toxicities.\n",
      "    *   The frequency of follow-up CT scans depends on the response to treatment and clinical stability.\n",
      "\n",
      "\n",
      "\n",
      "Running test with: openai embeddings | cosine retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "Based on the provided data, the patient's lung cancer is classified as follows:\n",
      "- **Tumor (T) Stage:** T1b (tumor ≤ 3 cm with significant spreading)\n",
      "- **Lymph Node (N) Stage:** N3 (metastasis to lymph nodes on the opposite side of the chest)\n",
      "- **Metastasis (M) Stage:** M1 (distant metastases present)\n",
      "\n",
      "Using the AJCC 8th Edition TNM staging for small cell lung cancer (SCLC), this classification indicates that the patient has **Extensive-Stage SCLC (ES-SCLC)**, as the disease has spread beyond the initial lung and regional lymph nodes into distant sites.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "Given the patient’s classification of Extensive-Stage Small Cell Lung Cancer (ES-SCLC), the following treatment plan is indicated:\n",
      "\n",
      "#### **Systemic Therapy:**\n",
      "- **Chemotherapy:** First-line treatment typically involves a combination of **etoposide and cisplatin or carboplatin**. This combination has demonstrated efficacy in patients with ES-SCLC. The regimen is usually administered over multiple cycles.\n",
      "  \n",
      "#### **Radiation Therapy:**\n",
      "- **Thoracic Radiation Therapy (TRT):** Considered for patients who demonstrate a good clinical response to chemotherapy. This may aid in potentially extending survival, particularly in cases with predominant thoracic disease.\n",
      "  \n",
      "#### **Prophylactic Cranial Irradiation (PCI):**\n",
      "- **Indication:** Recommended following a complete or near-complete response to initial therapy, as it may reduce the incidence of brain metastases despite no significant overall survival benefit shown in some studies.\n",
      "\n",
      "### 3. Therapeutic Modalities:\n",
      "- **Chemotherapy Regimen:** Etoposide + Cisplatin or Carboplatin\n",
      "- **Radiotherapy:** \n",
      "  - **Thoracic Radiation Therapy (TRT)** for localized symptoms or residual disease.\n",
      "  - **Prophylactic Cranial Irradiation (PCI)** as warranted.\n",
      "\n",
      "### 4. Clinical Trial Considerations:\n",
      "Given the patient’s SCLC status, clinical trials investigating new systemic therapies, including novel immunotherapy agents or advanced radiotherapy techniques, may be considered. Participation in clinical trials like those evaluating combination treatments or targeted therapies in ES-SCLC could provide additional options and contribute to research.\n",
      "\n",
      "### 5. Palliative and Supportive Care:\n",
      "- **Symptom Management:** Focus on managing symptoms related to metastases (e.g., cough, chest pain). Integration of palliative care services should be considered early, especially if there are significant symptoms impacting quality of life.\n",
      "- **Supportive Care:** Monitor for chemotherapy-related toxicities, manage side effects (nausea, fatigue), and consider interventions such as nutritional support.\n",
      "\n",
      "### 6. Follow-Up Plan:\n",
      "- **Surveillance:** Schedule follow-up imaging, such as CT scans, every 2-3 months initially, moving to longer intervals with stable disease. Monitor for signs of disease recurrence and manage any chemotherapy-related toxicities continuously.\n",
      "- **Patient Education:** Provide education on potential side effects of treatment, signs of progression, and the importance of adhering to follow-up appointments to ensure timely intervention if needed.\n",
      "\n",
      "In summary, the patient is classified with Extensive-Stage SCLC requiring systemic chemotherapy with potential thoracic radiation, careful monitoring, and supportive care integration for optimal management of her condition.\n",
      "\n",
      "\n",
      "Running test with: openai embeddings | cosine retrieval | gemini LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "- **AJCC TNM Stage:** T1b, N3, M1\n",
      "- **SCLC Stage:** Extensive-Stage SCLC (ES-SCLC)\n",
      "  - **Justification:** According to the American Cancer Society, extensive stage means that the cancer has spread to the other lung, to lymph nodes on the other side of the chest, or to distant organs. The presence of distant metastasis (M1) indicates that the cancer has spread beyond the locoregional confines, classifying it as extensive-stage SCLC.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "Given the diagnosis of extensive-stage SCLC (ES-SCLC) with T1b, N3, and M1 staging, the primary treatment approach is systemic therapy.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "- Systemic therapy is the primary treatment for ES-SCLC.\n",
      "- **Chemotherapy:** Not specified in provided documents\n",
      "- **Immunotherapy:** Not specified in provided documents\n",
      "- **Thoracic Radiation Therapy (TRT):** Thoracic radiation may be considered in responders to systemic therapy.\n",
      "- **Prophylactic Cranial Irradiation (PCI):** PCI or MRI surveillance of the brain should be considered after initial treatment in patients who respond to systemic therapy.\n",
      "\n",
      "### 4. Clinical Trial Considerations\n",
      "- Patients with ES-SCLC should be evaluated for ongoing clinical trials investigating immunotherapy, radiotherapy fractionation, and novel agents.\n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "- Initiate palliative care early to address symptoms related to brain metastases, superior vena cava syndrome, and paraneoplastic syndromes.\n",
      "- External beam radiation therapy (EBRT) can be used for the palliation of local symptomatic tumor growth. There is no consensus on which fractionation scheme should be used.\n",
      "\n",
      "### 6. Follow-Up Plan\n",
      "- Regular follow-up is crucial to monitor treatment response, detect recurrence, and manage potential complications.\n",
      "- Not specified in provided documents\n",
      "- Monitor chemotherapy-related toxicities\n",
      "\n",
      "\n",
      "\n",
      "Running test with: openai embeddings | bm25 retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### 1. Clinical Stage\n",
      "Based on the patient's **TNM classification**:\n",
      "- **Tumor (T)** stage: T1b (tumor ≤ 4 cm without pleural or chest wall invasion).\n",
      "- **Lymph Node (N)** stage: N3 (metastasis to supraclavicular or contralateral mediastinal lymph nodes).\n",
      "- **Metastasis (M)** stage: M1 (distant metastasis).\n",
      "\n",
      "According to the **AJCC 8th Edition** staging system for **small cell lung cancer (SCLC)**, the combined stage classification would be Stage **IV** due to the presence of distant metastasis (M1).\n",
      "\n",
      "Furthermore, with the categorization of SCLC, the patient's cancer is classified as **Extensive-Stage SCLC (ES-SCLC)**. **Justification**: The TNM classification indicates metastasis (M1) to distant organs, qualifying as extensive stage rather than limited stage where the cancer is restricted to a single hemithorax.\n",
      "\n",
      "### 2. Treatment Plan\n",
      "For **Extensive-Stage SCLC (ES-SCLC)**, the standard treatment includes:\n",
      "\n",
      "1. **Systemic therapy** as the primary treatment:\n",
      "   - **Chemotherapy Regimen:**\n",
      "     - **First-Line Treatment:**\n",
      "       - **Etoposide + Cisplatin** (EP) or **Etoposide + Carboplatin**.\n",
      "     - If the patient tolerates these regimens, continue for 4-6 cycles or until progression.\n",
      "\n",
      "2. **Radiation Therapy**:\n",
      "   - Consider **thoracic radiation therapy (TRT)** for patients who respond well to chemotherapy. This may improve overall survival.\n",
      "   - **Prophylactic cranial irradiation (PCI)** is recommended in patients with a complete or near-complete response to initial chemotherapy, aiming to reduce the risk of brain metastasis.\n",
      "\n",
      "3. **Supportive Care**: Conduct assessment for comorbidities to determine the tolerance of the planned treatment, focusing on quality of life improvements.\n",
      "\n",
      "### 3. Therapeutic Modalities\n",
      "- **Chemotherapy agents**:\n",
      "  - **Etoposide** (oral or IV administration).\n",
      "  - **Cisplatin or Carboplatin** (typically administered intravenously).\n",
      "  \n",
      "- **Radiotherapy modalities**:\n",
      "  - **Thoracic Radiation Therapy (TRT)** (dose typically around 30 Gy in 10 fractions over 2 weeks).\n",
      "  - **Prophylactic Cranial Irradiation (PCI)**—usually about 25 Gy in 10 fractions, especially advised post-chemotherapy if response is noted.\n",
      "\n",
      "### 4. Clinical Trial Considerations\n",
      "Consider enrolling in clinical trials that evaluate new combinations of chemotherapy, novel targeted therapies, or immunotherapy options that are described in ongoing phase II or III trials targeting extensive-stage SCLC to potentially benefit from cutting-edge treatments.\n",
      "\n",
      "### 5. Palliative and Supportive Care\n",
      "- **Symptom Management**: Address symptoms such as cough, dyspnea, and pain management. Employ palliative care strategies early in treatment.\n",
      "- **Supportive care services** should be involved to manage the psychological and physical impacts of cancer treatment.\n",
      "- Consider referrals for supportive counseling, nutrition, and lifestyle adjustments (e.g., smoking cessation support).\n",
      "\n",
      "### 6. Follow-Up Plan\n",
      "- Regular follow-up with assessments after every 2-3 cycles of chemotherapy to evaluate response via imaging (CT scans), physical examinations, and performance status evaluations.\n",
      "- Monitor for **chemotherapy-related toxicities**, especially for older adults, and adjust treatment regimens as necessary based on tolerance and side effects.\n",
      "\n",
      "**Frequency of follow-up**: After initial treatment, follow-up evaluations should be conducted every 3 months in the first year and then at longer intervals as clinically appropriate, including routine imaging as indicated by symptomatology or after treatment completion.\n",
      "\n",
      "It's crucial for the care team to engage with the patient continuously throughout treatment, providing education on what to expect at each step and managing side effects appropriately.\n",
      "\n",
      "\n",
      "Running test with: openai embeddings | bm25 retrieval | gemini LLM\n",
      "Response:\n",
      "## 1. Clinical Stage:\n",
      "\n",
      "*   **AJCC TNM Stage:** T1b, N3, M1\n",
      "*   **SCLC Stage:** Extensive-Stage SCLC (ES-SCLC). This is because the presence of distant metastasis (M1) automatically classifies the cancer as extensive stage, regardless of the T and N stages.\n",
      "\n",
      "## 2. Treatment Plan:\n",
      "\n",
      "Given the patient's diagnosis of Extensive-Stage SCLC (ES-SCLC), the primary treatment is systemic therapy.\n",
      "\n",
      "*   **Systemic Therapy:**\n",
      "    *   The standard first-line treatment consists of platinum-based chemotherapy, typically **etoposide + cisplatin or carboplatin**. This regimen aims to control the widespread disease.\n",
      "*   **Thoracic Radiation:**\n",
      "    *   Consider **thoracic radiation therapy (TRT)** in patients who demonstrate a response to chemotherapy. TRT can help improve local control of the primary tumor site, potentially prolonging survival.\n",
      "*   **Prophylactic Cranial Irradiation (PCI) or MRI Surveillance:**\n",
      "    *   **Prophylactic cranial irradiation (PCI)** should be considered for patients who achieve a complete or near-complete response to initial chemotherapy. If PCI is not administered, regular **MRI surveillance** of the brain is recommended to monitor for brain metastases.\n",
      "*   **Older Adults (≥70 years)**\n",
      "    *   The patient is 72 years old, so the treatment tolerance should be carefully evaluated, considering comorbidities and performance status.\n",
      "    *   **Hematologic toxicity** and **treatment-related mortality** are higher risks in older adults receiving standard chemoradiotherapy.\n",
      "    *   Treatment intensity may need to be adjusted accordingly, with consideration for **supportive care**, dose-reduction strategies, or even monotherapy if clinically indicated.\n",
      "    *   It's important to remember that while some data suggest survival equivalence in older adults who complete standard therapy, caution is needed when extrapolating trial data to this population.\n",
      "\n",
      "## 3. Therapeutic Modalities:\n",
      "\n",
      "*   **Chemotherapy:** Etoposide + Cisplatin or Carboplatin\n",
      "*   **Radiotherapy:** Thoracic Radiation Therapy (TRT), Prophylactic Cranial Irradiation (PCI)\n",
      "\n",
      "## 4. Clinical Trial Considerations:\n",
      "\n",
      "*   Based on the disease state and patient factors, the patient should be assessed for eligibility for relevant clinical trials investigating immunotherapy, radiotherapy fractionation, and novel agents.\n",
      "\n",
      "## 5. Palliative and Supportive Care:\n",
      "\n",
      "*   **Symptom Management:** Address potential complications such as brain metastases, superior vena cava syndrome, and paraneoplastic syndromes.\n",
      "*   **Early Integration of Palliative Services:** Integrate palliative care services early in the treatment course to optimize symptom control, quality of life, and patient-centered care.\n",
      "\n",
      "## 6. Follow-Up Plan:\n",
      "\n",
      "*   **Regular Monitoring:** Closely monitor the patient for chemotherapy-related toxicities.\n",
      "*   **Surveillance Imaging:** Implement a surveillance strategy that includes regular CT scans to assess treatment response and monitor for disease progression. The frequency of CT scans will depend on the patient's response to treatment and overall clinical status.\n",
      "\n",
      "\n",
      "\n",
      "Running test with: openai embeddings | combined retrieval | gpt-4o LLM\n",
      "Response:\n",
      "### Clinical Stage\n",
      "Based on the provided information, the patient's cancer can be classified using the AJCC 8th Edition TNM staging system. The components are as follows:\n",
      "\n",
      "- **Tumor (T) Stage:** T1b (tumor size is larger than 3cm but ≤ 4cm)\n",
      "- **Lymph Node (N) Stage:** N3 (involvement of contralateral supraclavicular, scalene, or more than one N2 station)\n",
      "- **Metastasis (M) Stage:** M1 (distant metastasis)\n",
      "\n",
      "Combining these classifications results in:\n",
      "- **Clinical Stage:** IV – Extensive-stage small cell lung cancer (ES-SCLC).\n",
      "\n",
      "#### Justification\n",
      "Small cell lung cancer is typically classified into two main categories: Limited Stage (LS) and Extensive Stage (ES). In this case, the presence of N3 and M1 indicates that there is significant lymph node involvement beyond the ipsilateral side (contralateral nodes) and that there are distant metastases, which fall into the criteria for Extensive Stage SCLC as per NCCN and AJCC guidelines.\n",
      "\n",
      "### Treatment Plan\n",
      "\n",
      "Given the extensive-stage classification, the primary goal is to implement a systemic therapy approach.\n",
      "\n",
      "#### Primary Treatment Recommendations for ES-SCLC:\n",
      "1. **Systemic Chemotherapy:**\n",
      "   - **Preferred Regimen:** \n",
      "     - **Etoposide + Carboplatin** or \n",
      "     - **Etoposide + Cisplatin**. \n",
      "   - The chemotherapy is typically administered for 4–6 cycles, depending on response and tolerance.\n",
      "\n",
      "2. **Radiotherapy:**\n",
      "   - Consider **thoracic radiation therapy (TRT)** for patients who show a complete or partial response to chemotherapy.\n",
      "   - Prophylactic Cranial Irradiation (PCI) should also be considered once significant response is achieved, especially if the patient has a good performance status (PS) post-chemotherapy.\n",
      "\n",
      "#### Management of Symptoms:\n",
      "- Palliative treatment modalities can be integrated for symptom management, which may include radiation therapy for specific symptoms like bone pain or for palliation in cases of brain metastases.\n",
      "\n",
      "#### Supportive Care:\n",
      "- Provide supportive care services to address potential side effects of treatment, such as antiemetics for nausea, growth factors for neutropenia, and pain management strategies.\n",
      "\n",
      "### Clinical Trial Considerations\n",
      "- Discuss potential enrollment in clinical trials exploring novel agents or combinations, particularly those focused on patients with extensive-stage SCLC, which may offer alternative therapeutic options not yet available standardly. Ongoing investigations into checkpoint inhibitors (such as durvalumab) and combination therapies could be especially relevant.\n",
      "\n",
      "### Palliative and Supportive Care\n",
      "Symptom-focused care should include:\n",
      "- Managing symptoms related to cancer itself (such as cough, dyspnea, and potential brain metastases).\n",
      "- Early integration of palliative services to improve the quality of life throughout the course of the disease.\n",
      "- Regular monitoring for complications associated with cancer treatment and disease progression.\n",
      "\n",
      "### Follow-Up Plan\n",
      "- Regular follow-up examinations every 4–6 weeks after starting treatment for clinical assessment and monitoring of toxicity.\n",
      "- Suggested imaging (CT scans) as per response evaluation, typically after every 2 cycles of chemotherapy.\n",
      "- Monitor for chemotherapy-related toxicities and overall performance status to adjust treatment plans accordingly.\n",
      "\n",
      "Heeding these directives will optimize therapeutic outcomes and enhance symptom management for the patient within the framework of extensive-stage SCLC.\n",
      "\n",
      "\n",
      "Running test with: openai embeddings | combined retrieval | gemini LLM\n",
      "Response:\n",
      "### 1. Clinical Stage:\n",
      "\n",
      "Based on the provided information:\n",
      "*   **T Stage:** T1b\n",
      "*   **N Stage:** N3\n",
      "*   **M Stage:** M1\n",
      "\n",
      "According to the TNM staging system, this patient has **Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**. The presence of distant metastasis (M1) automatically classifies SCLC as extensive stage.\n",
      "\n",
      "### 2. Treatment Plan:\n",
      "\n",
      "Given the patient's diagnosis of Extensive-Stage SCLC (ES-SCLC), the primary treatment strategy is systemic therapy.\n",
      "\n",
      "*   **Systemic Therapy**:\n",
      "    *   The recommended first-line chemotherapy regimen is typically a platinum-based agent (either **cisplatin** or **carboplatin**) combined with **etoposide**.\n",
      "    *   Immunotherapy, specifically the addition of **atezolizumab** or **durvalumab** to the platinum-etoposide regimen, has shown improved survival outcomes and is now a standard of care.\n",
      "\n",
      "*   **Thoracic Radiation Therapy (TRT)**:\n",
      "    *   For patients who demonstrate a response to initial chemotherapy, consolidation with thoracic radiation therapy may be considered to improve local control and potentially prolong survival.\n",
      "\n",
      "*   **Prophylactic Cranial Irradiation (PCI)**:\n",
      "    *   Given the propensity for SCLC to metastasize to the brain, prophylactic cranial irradiation (PCI) is a consideration for patients who achieve a complete or partial response to systemic therapy.\n",
      "    *   MRI surveillance can be considered if PCI is not administered.\n",
      "\n",
      "*   **Age Considerations (72 years old)**:\n",
      "    *   In older adults, treatment tolerance should be carefully evaluated based on comorbidities and performance status.\n",
      "    *   Due to the increased risk of hematologic toxicity and treatment-related mortality, dose reductions or alternative regimens may be necessary.\n",
      "    *   Supportive care should be optimized to manage potential side effects.\n",
      "\n",
      "### 3. Therapeutic Modalities:\n",
      "\n",
      "*   **Chemotherapy**:\n",
      "    *   **Cisplatin + Etoposide**\n",
      "    *   **Carboplatin + Etoposide**\n",
      "*   **Immunotherapy**:\n",
      "    *   **Atezolizumab**\n",
      "    *   **Durvalumab**\n",
      "*   **Radiotherapy**:\n",
      "    *   **Thoracic Radiation Therapy (TRT)**\n",
      "    *   **Prophylactic Cranial Irradiation (PCI)**\n",
      "\n",
      "### 4. Clinical Trial Considerations:\n",
      "\n",
      "Patients with ES-SCLC may be eligible for clinical trials investigating novel therapeutic strategies. These may include:\n",
      "*   New immunotherapy combinations\n",
      "*   Targeted therapies based on specific molecular markers\n",
      "*   Alternative radiotherapy fractionation schedules\n",
      "\n",
      "### 5. Palliative and Supportive Care:\n",
      "\n",
      "Palliative care should be integrated early in the management of ES-SCLC to address symptom control and improve quality of life.\n",
      "*   **Symptom Management**:\n",
      "    *   Brain metastases: Corticosteroids, whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS)\n",
      "    *   Superior vena cava syndrome: Corticosteroids, endovascular stenting, radiation therapy\n",
      "    *   Paraneoplastic syndromes: Management of specific hormonal or neurological manifestations\n",
      "*   **Supportive Care**:\n",
      "    *   Nutritional support\n",
      "    *   Pain management\n",
      "    *   Psychosocial support\n",
      "\n",
      "### 6. Follow-Up Plan:\n",
      "\n",
      "*   **Surveillance**:\n",
      "    *   Regular follow-up appointments (e.g., every 3-6 months for the first 2 years, then every 6-12 months) to monitor for recurrence or treatment-related complications.\n",
      "    *   CT scans of the chest and abdomen every 3-6 months for the first 2 years, then less frequently if the patient remains in remission.\n",
      "    *   Brain MRI every 6-12 months to monitor for brain metastases, especially if PCI was not administered.\n",
      "*   **Monitoring**:\n",
      "    *   Chemotherapy-related toxicities (e.g., myelosuppression, neuropathy, hearing loss)\n",
      "    *   Pulmonary function\n",
      "    *   Nutritional status\n",
      "    *   Psychosocial well-being\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "query_text = \"Based on the patient data and TMN staging what is the exact stage of the cancer and the indicated course of treatment?\"\n",
    "t_stage = \"T1b\"\n",
    "n_stage = \"N3\"\n",
    "m_stage = \"M1\"\n",
    "histopath_grade = \"\"\n",
    "cancer_type = \"Small cell carcinoma\"\n",
    "age = 72\n",
    "gender = \"Female\"\n",
    "additional_info = \"Not a smoker\"\n",
    "\n",
    "# Test different embeddings & retrieval methods\n",
    "for embedding in [\"gemini\", \"minilm\", \"openai\"]:\n",
    "    for retrieval in [\"cosine\", \"bm25\", \"combined\"]:\n",
    "        for llm in [\"gpt-4o\", \"gemini\"]:\n",
    "            print(f\"\\nRunning test with: {embedding} embeddings | {retrieval} retrieval | {llm} LLM\")\n",
    "            response = retrieval_and_response_pipeline(\n",
    "                query_text, embedding, retrieval, llm,\n",
    "                t_stage, n_stage, m_stage, histopath_grade, cancer_type, age, gender, additional_info\n",
    "            )\n",
    "            print(f\"Response:\\n{response}\\n\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
